Oncotype DX Breast DCIS Score®
Use
The Oncotype DX Breast DCIS Score test is used to help women and their doctors personalize treatment decisions for ductal carcinoma in situ (DCIS), a pre-invasive form of breast cancer. By evaluating the risk of local recurrence, it assists in determining whether more aggressive treatments like radiation therapy may be necessary or if they can be safely omitted. This test guides treatment to balance efficacy and reduce potential side effects from unnecessary treatments.
Special Instructions
The test helps differentiate between low-risk patients who might avoid unnecessary treatment and those who would benefit from more aggressive approaches. It is essential for patients and doctors to consider test results alongside clinical judgment and patient preferences.
Limitations
While the Oncotype DX Breast DCIS Score provides valuable information regarding the recurrence risk of DCIS, it should not be used as the sole basis for treatment decisions. Clinical factors and the broader medical context must also be considered. It predominantly applies to patients with DCIS and may not be indicative for other forms of breast cancer.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Formalin-fixed, paraffin-embedded (FFPE) tissue block
Collection Instructions
Submit a tissue block containing DCIS. Ensure proper labeling and secure packaging to prevent damage during transport.
Storage Instructions
Store at room temperature until analysis.
Causes for Rejection
Inadequate tissue sample, improper preservation, or mishandling during transport.
Other tests from different labs that may be relevant